Recent findings demonstrated that delivery of a stimulator of IFN gene (STING) agonists in tumor tissues upregulate the transcription of genes that encode type I IFNs, and proinflammatory cytokines and chemokines, which leads to the accumulation and infiltration of CD8+ T-cells and DC maturation, while repression of STINGs in TNBC promotes immune evasion and resistance to ICB18. This evidence concerns the gene STING1 and neoplasm.